Rifaximin delayed released
Small molecule
Rifaximin delayed released is one of 17 small molecule programs targeting Diverticulitis. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Diverticulitis
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Tylenol
KKenvue Brands
Approved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Lialda
TakedaPhase 3
Amoxicillin/clavulanic Acid
LundbeckApproved
Mesalazine
FerringPhase 3
Cipro
BayerPhase 2
Xifaxan
SSalix
Phase 2
Flagyl
DDePuy Orthopaedics
Phase 2
SPD476
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rifaximin delayed released. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- AAlfasigma S.p.A.